Partner Therapeutics Lands $35M DOD Contract for Leukine as COVID-19 Treatment

Massachusetts-based Partner Therapeutics has secured a $35 million contract from the Department of Defense for clinical trials of inhaled Leukine (sargramostim) for the treatment of COVID-19 patients with acute hypoxemia.

The first trial will begin this month across the U.S., under an investigational new drug application approved by the FDA in May.

The contract will also support regulatory filings for a possible Emergency Use Authorization and expanded production capacity.